Carcinoma, Neuroendocrine: all 238 studies
Page 2 of 3. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.
- TheraSphere for the Treatment of Liver MetastasesCompletedNCT00511862Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
- Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
- Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
- A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerCompletedNCT00358956Phase 2Results posted
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedNCT00113360Phase 2Results posted
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsActive, not recruitingNCT07129252Phase 1/2
- ML Decision Model for G-NEC Adjuvant TherapyCompletedNCT06663852
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesActive, not recruitingNCT06577987Phase 1
- PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANECStatus unknownNCT06400654
- Predictive Factors for Medullary Thyroid Cancer AggressivenessCompletedNCT06292988
- Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerWithdrawnNCT06094842Phase 1
- Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.CompletedNCT06067594
- Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine CarcinomaCompletedNCT05714722
- the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine CarcinomaCompletedNCT05671393
- Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After PancreatoduodenectomyStatus unknownNCT05641233Phase 1/2
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine CarcinomasCompletedNCT05619744Phase 1
- Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsActive, not recruitingNCT05599984Phase 1
- Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersWithdrawnNCT05582031Phase 2
- A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungActive, not recruitingNCT05470595Phase 2
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
- Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETTerminatedNCT05420636Phase 2
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersSuspendedNCT05337735Phase 2
- NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1
- Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
- Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
- Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
- Neuroendocrine Tumors - Patient Reported OutcomesActive, not recruitingNCT05064150
- Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
- A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)Status unknownNCT04787328Phase 2
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnNCT04760288Phase 3
- Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine CarcinomaCompletedNCT04705519Phase 2
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
- Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasStatus unknownNCT04635956Phase 2
- The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin TumorsStatus unknownNCT04583605
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
- A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3Active, not recruitingNCT04524208Phase 2
- Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)sTerminatedNCT04488263
- Assessment of What Patients and Healthcare Providers ValueCompletedNCT04483349
- Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive OncologyCompletedNCT04478175Not applicable
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
- PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic TreatmentStatus unknownNCT04331912
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
- Temozolomide for Second-Line Treatment of Neuroendocrine CarcinomasCompletedNCT04122911Phase 2
- Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
- Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI TractCompletedNCT04069299
- Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaStatus unknownNCT03992911Phase 2/3
- Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaWithdrawnNCT03901378Phase 2
- Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of AccuracyStatus unknownNCT03884179
- Inhaled Essential Oil Effect on Common QOL Concerns During Cancer TreatmentCompletedNCT03858855Not applicable
- Ponatinib in Advanced or Metastatic Medullary Thyroid CancerWithdrawnNCT03838692Phase 2
- Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaCompletedNCT03837977Phase 2
- Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine NeoplasmsCompletedNCT03834701Not applicable
- Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort StudyCompletedNCT03774862
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive, not recruitingNCT03647163Phase 1/2
- 18F-Fluorocholine PET/CT in Medullary Thyroid CancerStatus unknownNCT03643055
- Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid CarcinomaStatus unknownNCT03636945Not applicable
- Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine CancersWithdrawnNCT03623984Early Phase 1
- Pancreatic Cancer Dietary Assessment StudyCompletedNCT03616431
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruitingNCT03600233Phase 2
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
- CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasTerminatedNCT03387592Phase 2
- Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After ChemotherapyCompletedNCT03352934Phase 2
- Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)CompletedNCT03305133
- Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine CarcinomaStatus unknownNCT03279614Phase 2
- Avelumab in G3 NECCompletedNCT03278405Phase 1/2
- Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTCCompletedNCT03246659Phase 1
- Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine CarcinomaStatus unknownNCT03168607Phase 2
- Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine CarcinomaTerminatedNCT03168594Phase 2
- Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03147404Phase 2
- Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03110978Phase 2
- TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03079440Phase 2
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
- Secured Access to Pembrolizumab for Patients With Selected Rare Cancer TypesCompletedNCT03012620Phase 2
- Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in HumansStatus unknownNCT02970786Phase 1
- Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine CarcinomaStatus unknownNCT02943798Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary CancerCompletedNCT02820857Phase 2
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
- uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungStatus unknownNCT02755675Phase 2
- Personalized PRRT of Neuroendocrine TumorsActive, not recruitingNCT02754297Phase 2
- Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary OriginStatus unknownNCT02695459Phase 2
- Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginActive, not recruitingNCT02687958Phase 2
- Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)CompletedNCT02586350Phase 2/3
- SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine CarcinomaTerminatedNCT02500914Phase 1
- Assessing Quality of Life Tools in Medullary Thyroid Cancer PatientsCompletedNCT02465424
- Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas PatientsCompletedNCT02457273Phase 2
- Octreotide LAR as Maintenance Treatment for Patients With NECStatus unknownNCT02409849Phase 2
- Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With VandetanibCompletedNCT02268734
- KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic TumorsCompletedNCT02250885Phase 2
- Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)CompletedNCT02248012Phase 2
- An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive TumoursActive, not recruitingNCT02236910Phase 2
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedNCT02230176Phase 2
- A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine CarcinomasStatus unknownNCT02215447Phase 2
- An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver MetastasisCompletedNCT02205515Phase 1/2